NL1002833C2 - Werkwijze, voor duurzame ontwenning van/aan nicotine en andere verslavende producten door toediening van sex steroide voorlopers (precursors), alsmede het gebruik van die voorlopers als medicijn. - Google Patents
Werkwijze, voor duurzame ontwenning van/aan nicotine en andere verslavende producten door toediening van sex steroide voorlopers (precursors), alsmede het gebruik van die voorlopers als medicijn. Download PDFInfo
- Publication number
- NL1002833C2 NL1002833C2 NL1002833A NL1002833A NL1002833C2 NL 1002833 C2 NL1002833 C2 NL 1002833C2 NL 1002833 A NL1002833 A NL 1002833A NL 1002833 A NL1002833 A NL 1002833A NL 1002833 C2 NL1002833 C2 NL 1002833C2
- Authority
- NL
- Netherlands
- Prior art keywords
- precursors
- sex steroid
- nicotine
- addictive
- chemical
- Prior art date
Links
- 239000002243 precursor Substances 0.000 title claims abstract description 32
- 239000003163 gonadal steroid hormone Substances 0.000 title claims abstract description 16
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 12
- 229960002715 nicotine Drugs 0.000 title claims abstract description 12
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 title claims description 7
- 239000000126 substance Substances 0.000 claims abstract description 18
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims abstract description 13
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims abstract description 7
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 10
- 229960002847 prasterone Drugs 0.000 claims description 10
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229950009829 prasterone sulfate Drugs 0.000 claims description 5
- 235000019788 craving Nutrition 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract description 2
- 229960001948 caffeine Drugs 0.000 abstract description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 abstract 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 229960002069 diamorphine Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229960001797 methadone Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940095172 subutex Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1002833A NL1002833C2 (nl) | 1996-04-10 | 1996-04-10 | Werkwijze, voor duurzame ontwenning van/aan nicotine en andere verslavende producten door toediening van sex steroide voorlopers (precursors), alsmede het gebruik van die voorlopers als medicijn. |
| DE69703877T DE69703877T2 (de) | 1996-04-10 | 1997-04-10 | Verwendung von dehydroepiandrosteron zur suchtbehandlung |
| EP97920642A EP0888116B1 (de) | 1996-04-10 | 1997-04-10 | Verwendung von dehydroepiandrosteron zur suchtbehandlung |
| AT97920642T ATE198549T1 (de) | 1996-04-10 | 1997-04-10 | Verwendung von dehydroepiandrosteron zur suchtbehandlung |
| PCT/EP1997/001779 WO1997037663A1 (en) | 1996-04-10 | 1997-04-10 | Use of dehydroepiandrosterone for the treatment of addictions |
| AU26952/97A AU2695297A (en) | 1996-04-10 | 1997-04-10 | Use of dehydroepiandrosterone for the treatment of addictions |
| ES97920642T ES2155685T3 (es) | 1996-04-10 | 1997-04-10 | Utilizacion de deshidroepiandrosterona para el tratamiento de adicciones. |
| US09/283,228 US6194400B1 (en) | 1996-04-10 | 1999-04-01 | Use of amino acid precursors for the treatment of addictions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1002833A NL1002833C2 (nl) | 1996-04-10 | 1996-04-10 | Werkwijze, voor duurzame ontwenning van/aan nicotine en andere verslavende producten door toediening van sex steroide voorlopers (precursors), alsmede het gebruik van die voorlopers als medicijn. |
| NL1002833 | 1996-04-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL1002833A1 NL1002833A1 (nl) | 1996-08-12 |
| NL1002833C2 true NL1002833C2 (nl) | 1997-04-03 |
Family
ID=19762655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL1002833A NL1002833C2 (nl) | 1996-04-10 | 1996-04-10 | Werkwijze, voor duurzame ontwenning van/aan nicotine en andere verslavende producten door toediening van sex steroide voorlopers (precursors), alsmede het gebruik van die voorlopers als medicijn. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6194400B1 (de) |
| EP (1) | EP0888116B1 (de) |
| AT (1) | ATE198549T1 (de) |
| AU (1) | AU2695297A (de) |
| DE (1) | DE69703877T2 (de) |
| ES (1) | ES2155685T3 (de) |
| NL (1) | NL1002833C2 (de) |
| WO (1) | WO1997037663A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20080286340A1 (en) * | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered nicotine containing products |
| US20080286341A1 (en) * | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered coated nicotine containing products |
| US10912806B2 (en) | 2018-09-26 | 2021-02-09 | Michael MCGOWAN | Composition comprising an essential oil and its packaging thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
-
1996
- 1996-04-10 NL NL1002833A patent/NL1002833C2/nl not_active IP Right Cessation
-
1997
- 1997-04-10 AU AU26952/97A patent/AU2695297A/en not_active Abandoned
- 1997-04-10 ES ES97920642T patent/ES2155685T3/es not_active Expired - Lifetime
- 1997-04-10 AT AT97920642T patent/ATE198549T1/de not_active IP Right Cessation
- 1997-04-10 WO PCT/EP1997/001779 patent/WO1997037663A1/en not_active Ceased
- 1997-04-10 DE DE69703877T patent/DE69703877T2/de not_active Expired - Fee Related
- 1997-04-10 EP EP97920642A patent/EP0888116B1/de not_active Expired - Lifetime
-
1999
- 1999-04-01 US US09/283,228 patent/US6194400B1/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| B. BUDZISZEWSKA ET AL.: "Neurosteroids and the naloxone-precipitated withdrawal syndrome in morphine dpendent mice.", EUR. NEUROPSYCHOPHARMACOL., vol. 6, no. 2, 1996, pages 135 - 140, XP000612742 * |
| F. FACCHINETTI ET AL: "Reduced estriol and dehydroepiandrosterone sulphate plasma levels in methadone-addicted pregnant women.", EUR. J. OBSTET. GYNECOL., vol. 23, no. 1-2, 1986, pages 67 - 73, XP000612727 * |
| S. SCHWARZ ET AL.: "Steroids and opiate receptors.", J. STEROID BIOCHEM., vol. 48, no. 4, 1994, pages 391 - 402, XP002020985 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2155685T3 (es) | 2001-05-16 |
| EP0888116B1 (de) | 2001-01-10 |
| WO1997037663A1 (en) | 1997-10-16 |
| NL1002833A1 (nl) | 1996-08-12 |
| ATE198549T1 (de) | 2001-01-15 |
| DE69703877T2 (de) | 2001-08-16 |
| DE69703877D1 (de) | 2001-02-15 |
| EP0888116A1 (de) | 1999-01-07 |
| US6194400B1 (en) | 2001-02-27 |
| AU2695297A (en) | 1997-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100891568B1 (ko) | 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법 | |
| JP4729148B2 (ja) | 痛みの管理及び解毒のための鼻腔及び眼球へのケタミン投与 | |
| EP3049059B1 (de) | Intranasale dhe formulierung zur behandlung von kopfschmerzen | |
| JP2019537628A (ja) | 併用療法 | |
| Kaufman et al. | An evaluation of the effects of sucrose on neonatal pain with 2 commonly used circumcision methods | |
| JP2003534286A (ja) | 勃起障害症状改善のために、刺激物質の活性成分としてプロアントシアニジン、一酸化窒素源としてｌアルギニン又はその塩の使用 | |
| Pontiroli et al. | Selective and extremely long inhibition of prolactin release in man by 1‐ethyl‐3‐(3′‐dimethylaminopropyl)‐3‐(6′‐allylergoline‐8′‐beta‐carbonyl)‐urea‐diphosphate (FCE 21336). | |
| WO2006002096A2 (en) | Low doses of l-citrulline for treating diseases | |
| US5073555A (en) | Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels | |
| TWI760194B (zh) | 一種改善睡眠品質的飲用水 | |
| SE516468C2 (sv) | Användning av ett extrakt från Morinda citrifolia L. för framställning av läkemedel för behandling av tinnitus. | |
| JP2022514340A (ja) | 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法 | |
| US5162113A (en) | Oral composition for treating bone disorders | |
| DE69703877T2 (de) | Verwendung von dehydroepiandrosteron zur suchtbehandlung | |
| US20100015261A1 (en) | Herbal preparation for sleep apnea relief | |
| EP1425026B1 (de) | Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe | |
| KR0185539B1 (ko) | 종합기침약 및 그의 제조방법 | |
| US20220079982A1 (en) | Formulation for treating tobacco or psychotrope withdrawal symptoms | |
| CN100413512C (zh) | 银杏提取物用于增加肌肉质量而减少脂肪质量的用途 | |
| TW202310829A (zh) | 夜間頻尿、中途覺醒或頻尿的預防或改善劑 | |
| Haase et al. | Open Study with Bromperidol (CC 2489), a new Neuroleptic, for the Determination of the Neuroleptic Threshold and the Neuroleptic-Therapeutic Range | |
| Wortsman et al. | Mechanism for the hypotestosteronemia of the sleep apnea syndrome | |
| KR20030041370A (ko) | 성기능 장애 치료용 생약 조성물 | |
| CA2394079C (en) | Weight promoting composition, method and product | |
| Truter | Evidence Based Pharmacy Practice: cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AD1A | A request for search or an international type search has been filed | ||
| RD2N | Patents in respect of which a decision has been taken or a report has been made (novelty report) |
Effective date: 19970128 |
|
| PD2B | A search report has been drawn up | ||
| VD1 | Lapsed due to non-payment of the annual fee |
Effective date: 20041101 |